{
    "clinical_study": {
        "@rank": "38603", 
        "acronym": "Havasu", 
        "arm_group": {
            "arm_group_label": "Idelalisib + rituximab", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years)."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the effect of treatment with idelalisib (IDELA) plus rituximab on\n      overall response rate (ORR); onset, magnitude, and duration of disease control (including\n      duration of response [DOR], progression free survival [PFS], and overall survival [OS]); and\n      minimal residual disease (MRD) in subjects with previously untreated chronic lymphocytic\n      leukemia (CLL) with 17p deletion. In addition, the study will evaluate the safety profile\n      observed with the combination of IDELA and rituximab."
        }, 
        "brief_title": "Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion", 
        "completion_date": {
            "#text": "July 2024", 
            "@type": "Anticipated"
        }, 
        "condition": "B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented diagnosis of B-cell CLL, according to International Workshop on Chronic\n             Lymphocytic Leukemia\n\n          -  Presence of 17p deletion in CLL cells as demonstrated by FISH testing\n\n          -  No prior therapy for CLL other than corticosteroids for disease complications.\n\n          -  CLL that warrants treatment\n\n          -  Presence of measurable lymphadenopathy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2\n\n        Exclusion Criteria:\n\n          -  Current or prior histological transformation from CLL to an aggressive lymphoma (ie,\n             Richter transformation).\n\n          -  Known presence of myelodysplastic syndrome.\n\n          -  History of a non-CLL malignancy except for the following:\n\n               -  the malignancy has been in remission without treatment for \u2265 5 years prior to\n                  enrollment, or\n\n               -  carcinoma in situ of the cervix, or\n\n               -  adequately treated basal or squamous cell skin cancer or other localized\n                  non-melanoma skin cancer, or\n\n               -  asymptomatic prostate cancer without known metastatic disease and with no\n                  current requirement for therapy or requiring only hormonal therapy and with\n                  normal prostate specific antigen for \u2265 1 year prior to enrollment, or\n\n               -  ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or\n\n               -  other adequately treated Stage 1 or 2 cancer currently in complete remission\n\n          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of\n             enrollment\n\n          -  Ongoing liver injury\n\n          -  Ongoing drug-induced pneumonitis.\n\n          -  Ongoing inflammatory bowel disease.\n\n          -  History of prior allogeneic bone marrow progenitor cell or solid organ\n             transplantation.\n\n          -  Ongoing immunosuppressive therapy other than corticosteroids.\n\n          -  Concurrent participation in another therapeutic clinical trial.\n\n          -  Prior or ongoing clinically significant illness, medical condition, surgical history,\n             physical finding, electrocardiogram (ECG) finding, or laboratory abnormality"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044822", 
            "org_study_id": "GS-US-312-0133", 
            "secondary_id": "2013-003314-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "Idelalisib + rituximab", 
                "description": "Idelalisib 150 mg tablets administered orally twice daily", 
                "intervention_name": "Idelalisib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-1101", 
                    "CAL-101"
                ]
            }, 
            {
                "arm_group_label": "Idelalisib + rituximab", 
                "description": "Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Rituxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Lymphocytic Leukemia", 
            "CLL"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion", 
        "overall_contact": {
            "email": "Apollo.Madayag@gilead.com", 
            "last_name": "Apollo Madayag", 
            "phone": "650-577-6925"
        }, 
        "overall_contact_backup": {
            "email": "Ori.Yellin@gilead.com", 
            "last_name": "Ori Yellin", 
            "phone": "650-372-7643"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Ron Dubowy, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Health and Medicines Authority", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Hungary: National Institute of Pharmacy", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Portugal: INFARMED, National Authority of Medicines and Health Products, IP", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Switzerland: Swissmedic", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR).", 
            "measure": "Overall Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044822"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Duration of response (DOR) is defined as the interval from the first documentation of CR or PR to the first documentation of definitive disease progression or death from any cause.", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Complete response (CR) rate is defined as the proportion of participants who achieve a CR", 
                "measure": "Complete Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Progression-free survival (PFS) is defined as the interval from the first dose of study drug to the first documentation of definitive disease progression or death from any cause.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "UP to 10 years"
            }, 
            {
                "description": "Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD <10^-4, as assessed by flow cytometry in bone marrow at Week 36 after therapy initiation.", 
                "measure": "Minimal residual disease negativity rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions.", 
                "measure": "Nodal response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Overall survival (OS) is defined as the interval from the start of study treatment to death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}